Table 1 Demographic and clinical characteristics for patients with DHL vs DEL vs other (non-DHL and non-DEL).
DHL n (%) | DEL n (%) | Other n (%) | P value | |
|---|---|---|---|---|
Numbera | 80 | 74 | 179 | -- |
Age at CAR-T, median | 58 | 60 | 59 | 0.6 |
Female sex | 31 (40.8) | 28 (39.4) | 59 (34.7) | 0.6 |
De novo DLBCL | 61 (76.3) | 56 (75.7) | 146 (81.6) | 0.5 |
GCB COO | 41 (87.2) | 36 (58.1) | 82 (54.7) | <0.001 |
IPI ≥4 at diagnosis | 12 (21.1) | 13 (21.0) | 27 (18.6) | 0.9 |
Elevated LDH at diagnosis | 41 (80.4) | 44 (74.6) | 80 (58.4) | 0.006 |
LDH elevated at apheresis | 44 (61.1) | 32 (45.1) | 90 (53.9) | 0.2 |
Stage ≥3 at diagnosis | 68 (89.5) | 61 (87.1) | 135 (80.4) | 0.1 |
Bulky disease at diagnosis | 24 (31.2) | 27 (39.7) | 36 (21.2) | 0.01 |
CAR-T given second line | 16 (20.0) | 9 (12.2) | 19 (10.6) | 0.1 |
AutoHCT prior to CART | 15 (19.7) | 22 (31.0) | 48 (28.2) | 0.3 |
Bridging therapy | 29 (38.2) | 43 (60.6) | 76 (44.7) | 0.02 |
R/R within 12 mon of initial CIT | 59 (74.7) | 46 (62.2) | 116 (66.3) | 0.2 |
Time apheresis to CAR-T, mon, median | 1.1 | 0.9 | 1.1 | 0.9 |
CAR-T on clinical trial | 25 (31.3) | 11 (15.1) | 46 (25.7) | 0.06 |
CAR-T product | 0.3 | |||
Axi-cel | 54 (67.5) | 51 (69.9) | 112 (62.9) | -- |
Tisa-cel | 21 (26.3) | 16 (21.9) | 40 (22.5) | -- |
Liso-cel | 5 (6.3) | 6 (8.2) | 26 (14.6) | -- |
Grade ≥3 CRS | 14 (23.0) | 10 (17.9) | 19 (14.1) | 0.3 |
Grade ≥3 ICANS | 15 (30.6) | 17 (38.6) | 34 (34.0) | 0.7 |
